Dr. Onder Alpdogan and Dr. Jianqing Lin Granted ACS-IRG Awards

6
Sep

Congratulations to Dr. Onder Alpdogan and Dr. Jianqing Lin for each being selected recipients of an ACS-IRG award.

The American Cancer Society-Institutional Research Grants (ACS-IRG) are designed to provide seed money to support junior faculty members with an interest in cancer research. The ACS defines junior faculty as investigators at the rank of assistant professor or equivalent who are eligible to apply as a principal investigator for grant support from national agencies.

Jianqing Lin, M.D., assistant professor of medical oncology


Dr. Lin’s Research Overview
The current proposal is a continuation of the concept that digoxin is an inhibitor of HIF-1a that will subsequently slow the growth of prostate cancer progression. Since the drug has minimal toxicity, it would be an ideal therapy to explore in other disease states in prostate cancer. With the awareness of over-treatment and treatment related complications in men with low-risk localized prostate cancer patients are willing to be on active surveillance. This current proposal is to examine the effects of digoxin to delay or reverse prostate cancer progression, with significant effort on tissue acquisition and to understand the molecular pathway affected with the treatment of digoxin. This study will shed light on the effects of future HIF-1a inhibitors for the treatment of prostate cancer and the foundation for future NIH funding.

Dr. Alpdogan’s Research Overview

Onder Alpdogan, M.D., assistant professor of medical oncology

Use of haploidentical HSCT in the treatment of advanced/relapsed RCC is a novel idea and has never been studied in preclinical models. We believe that haploidentical transplant model is a better platform to develop immunotherapy to solid tumors specificall renal cell carcinoma. Immunological response would be faster than other transplant models because of MHC disparity. This innovative new approach might give us an opportunity to develop new treatment strategies for patients with resistant/relapsed RCC after exhausting standard therapy including cytokine (IL-2) and Tyrosine Kinase Inhibitors (TKIs). These studies will not only generate new information about clinically relevant treatment strategies, but also provide substantial new findings about stem cell biology and transplantation.